Microbiome Drug Articles & Analysis
33 news found
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as ...
Phase 3 ECOSPOR III Study of SER-109 Data Encore Cancer patients are at greater risk of developing rCDI and tend to have worse outcomes, due to their weakened immune system and frequent antibiotics exposure.i Encore data from the completed double-blind, randomized, placebo-controlled Phase 3 ECOSPOR III trial (NCT03183128) show that the investigational microbiome therapeutic ...
Infant Bacterial Therapeutics AB (publ) (IBT) is a pharmaceutical company with a product in clinical phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the ...
Food and Drug Administration (FDA) in mid-2022, positioning SER-109 up to potentially become the first ever FDA-approved microbiome-based therapeutic for treating recurrent C. difficile infections with a potential product launch in the first half of 2023. ...
According to published clinical data from Memorial Sloan Kettering, patients undergoing this type of transplant who have less diverse gut flora are significantly more likely than patients with a richer microbiome to experience infection or GvHD. The trial will help inform whether SER-155 can restore a healthy microbiome and support transplant recovery. About ...
Seres expects to finalize a Biologics License Application (BLA) submission for SER-109 with the U.S. Food and Drug Administration (FDA) in mid-2022. “We are eager to showcase new data that further validate the potential of our investigational microbiome therapeutic, SER-109, at the world’s largest gathering of physicians and researchers in the ...
--(BUSINESS WIRE)--May 4, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. ...
The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system. Harnessing its unique expertise in the microbiome, Axial is developing small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the ...
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut ...
ByBio-Me
The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel ...
The Pharmabiotics Conference brings together players from academia and industry and it is an incredible opportunity to meet stakeholders and discuss the further innovation in microbiome-based drug products and regulatory affairs. Reach out to us if you want to meet during the conference event or to receive any further information about Microviable. ...
About AB-2004 AB-2004 is a first-in-class, molecular therapeutic that targets the microbiome gut-brain axis and its role in co-occurring conditions associated with ASD. ...
Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a product in clinical phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to ...
“The data highlighted in Nature Medicine further support our novel therapeutic strategy focused on specific targets in the gut microbiome. We strongly believe that AB-2004 can improve the quality of life of many children with ...
“By starting to identify how bacterial metabolites in the gut can impact behavior, it offers a tremendous opportunity to discover and validate new drug targets in the gut microbiome that may lead to novel medical interventions for the treatment of neurological conditions that adversely affect quality of ...
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational ...
He has been a valued leader at large companies (3M) and emerging startups (Rion, StemoniX, Rebiotix) where he made significant contributions to the pioneering development of regenerative exosome and microbiome therapeutics, 3D organoids for drug discovery, and novel drug delivery technologies. ...
Axial’s gut-targeted approach minimizes the potential for side effects due to a lack of systemic exposure to the drug. Axial is evaluating AB-2004 in a Phase 2b clinical trial based upon a large body of existing human safety data. ...
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 6thMicrobiome Movement – Drug Development Summit Europe 2022 in London during January 25th-27th, 2022. The presentation has been included in stream A titled “Understanding mechanisms of action & preclinical development” the 26th at 13.45. Microbiota Adaptation ...
Axial’s gut-targeted approach minimizes the potential for side effects due to a lack of systemic exposure to the drug. Axial is evaluating AB-2004 in a Phase 2b clinical trial based upon a large body of existing human safety data. ...